Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × MLN8054 × Clear all
NCT00652158 2013-09-23

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
44 enrolled

Advanced Malignancies

NCT00249301 2008-04-01

A Study of MLN8054 in Patients With Advanced Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
63 enrolled
BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡